275 related articles for article (PubMed ID: 17057207)
21. Immune dysfunction in inflammatory bowel disease.
Neuman MG
Transl Res; 2007 Apr; 149(4):173-86. PubMed ID: 17383591
[TBL] [Abstract][Full Text] [Related]
22. Chemokines as novel therapeutic targets for inflammatory bowel disease.
Nishimura M; Kuboi Y; Muramoto K; Kawano T; Imai T
Ann N Y Acad Sci; 2009 Sep; 1173():350-6. PubMed ID: 19758172
[TBL] [Abstract][Full Text] [Related]
23. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature.
Wagner JG; Roth RA
Pharmacol Rev; 2000 Sep; 52(3):349-74. PubMed ID: 10977867
[TBL] [Abstract][Full Text] [Related]
24. Targeting of Neutrophil Lewis X Blocks Transepithelial Migration and Increases Phagocytosis and Degranulation.
Brazil JC; Sumagin R; Cummings RD; Louis NA; Parkos CA
Am J Pathol; 2016 Feb; 186(2):297-311. PubMed ID: 26687991
[TBL] [Abstract][Full Text] [Related]
25. The enteric nervous system as a regulator of intestinal epithelial barrier function in health and disease.
Snoek SA; Verstege MI; Boeckxstaens GE; van den Wijngaard RM; de Jonge WJ
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):637-51. PubMed ID: 20932148
[TBL] [Abstract][Full Text] [Related]
26. Pathobiology of neutrophil-epithelial interactions.
Brazil JC; Parkos CA
Immunol Rev; 2016 Sep; 273(1):94-111. PubMed ID: 27558330
[TBL] [Abstract][Full Text] [Related]
27. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
28. Escherichia coli type 1 pili trigger late IL-8 production by neutrophil-like differentiated PLB-985 cells through a Src family kinase- and MAPK-dependent mechanism.
Sémiramoth N; Gleizes A; Turbica I; Sandré C; Gorges R; Kansau I; Servin A; Chollet-Martin S
J Leukoc Biol; 2009 Feb; 85(2):310-21. PubMed ID: 19015376
[TBL] [Abstract][Full Text] [Related]
29. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease.
Naito Y; Takagi T; Yoshikawa T
J Gastroenterol; 2007 Oct; 42(10):787-98. PubMed ID: 17940831
[TBL] [Abstract][Full Text] [Related]
30. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S
Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil migration across the intestinal epithelial barrier--summary of in vitro data and description of a new transgenic mouse model with doxycycline-inducible interleukin-8 expression in intestinal epithelial cells.
Kucharzik T; Williams IR
Pathobiology; 2002-2003; 70(3):143-9. PubMed ID: 12571418
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil migration across tight junctions is mediated by adhesive interactions between epithelial coxsackie and adenovirus receptor and a junctional adhesion molecule-like protein on neutrophils.
Zen K; Liu Y; McCall IC; Wu T; Lee W; Babbin BA; Nusrat A; Parkos CA
Mol Biol Cell; 2005 Jun; 16(6):2694-703. PubMed ID: 15800062
[TBL] [Abstract][Full Text] [Related]
33. Review article: Pathobiology of neutrophil interactions with intestinal epithelia.
Madara JL
Aliment Pharmacol Ther; 1997 Dec; 11 Suppl 3():57-62; discussion 62-3. PubMed ID: 9467979
[TBL] [Abstract][Full Text] [Related]
34. Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease.
Zhou GX; Liu ZJ
J Dig Dis; 2017 Sep; 18(9):495-503. PubMed ID: 28857501
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil migration across intestinal epithelium.
Jaye DL; Parkos CA
Ann N Y Acad Sci; 2000; 915():151-61. PubMed ID: 11193572
[TBL] [Abstract][Full Text] [Related]
36. Microbial influences in inflammatory bowel diseases.
Sartor RB
Gastroenterology; 2008 Feb; 134(2):577-94. PubMed ID: 18242222
[TBL] [Abstract][Full Text] [Related]
37. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
Van Assche G; Vermeire S; Rutgeerts P
Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811
[TBL] [Abstract][Full Text] [Related]
38. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease.
Hatoum OA; Heidemann J; Binion DG
Ann N Y Acad Sci; 2006 Aug; 1072():78-97. PubMed ID: 17057192
[TBL] [Abstract][Full Text] [Related]
39. Adrenomedullin treatment reduces intestinal inflammation and maintains epithelial barrier function in mice administered dextran sulphate sodium.
Ashizuka S; Inagaki-Ohara K; Kuwasako K; Kato J; Inatsu H; Kitamura K
Microbiol Immunol; 2009 Oct; 53(10):573-81. PubMed ID: 19780971
[TBL] [Abstract][Full Text] [Related]
40. Deposition of microparticles by neutrophils onto inflamed epithelium: a new mechanism to disrupt epithelial intercellular adhesions and promote transepithelial migration.
Butin-Israeli V; Houser MC; Feng M; Thorp EB; Nusrat A; Parkos CA; Sumagin R
FASEB J; 2016 Dec; 30(12):4007-4020. PubMed ID: 27553226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
